Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

242 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is to compare the 2 Groups with respect to antibody responses to inactivated influenza vaccine.

Observational Objectives:

* To describe the percentage of participants with protective Hemagglutinin (HAI) antibody titers to each of the 3 vaccine antigens in both study groups following each vaccination.
* To describe the HAI geometric mean titer (GMTs) to each of the 3 vaccine antigens in both study groups following each vaccination.
* To describe the safety of the 2005-2006 pediatric formulation of Fluzone® vaccine in both study groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

NCT00858468

Influenza

COMPLETED PHASE1/PHASE2

Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine

NCT00258830

Influenza

COMPLETED PHASE4

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

NCT00831987

Influenza

COMPLETED PHASE4

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

NCT00743275

Influenza

COMPLETED PHASE4

Study of Safety and Immunogenicity of Fluzone® in Healthy Children

NCT00831675

Influenza

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a descriptive study that will provide preliminary comparative information about the safety and immunogenicity of Fluzone® vaccine among children who were given Fluzone® vaccine at 2 months of age (Study GRC27 NCT00858468)and those who never received influenza vaccine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fluzone® Vaccine-Primed Group

Participants received 2 doses of Fluzone® vaccine at 2 months (in Study GRC 27)

Group Type EXPERIMENTAL

Influenza Virus Vaccine

Intervention Type BIOLOGICAL

0.25 mL, Intramuscular

Influenza Vaccine-Naive Group

Participants who have never received influenza vaccine (and not in Study GRC27)

Group Type ACTIVE_COMPARATOR

Influenza Virus Vaccine

Intervention Type BIOLOGICAL

0.25 mL, Intramuscular

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Influenza Virus Vaccine

0.25 mL, Intramuscular

Intervention Type BIOLOGICAL

Influenza Virus Vaccine

0.25 mL, Intramuscular

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fluzone® 2005-2006 Pediatric Formulation Fluzone® 2005-2006 Pediatric Formulation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant is between 6 and 10 months of age on the day of inclusion (has reached 6-month but has not reached 11-month anniversary of birth).
* Available for the duration of the study.
* Born at full term of pregnancy (≥ 36 weeks) with a birth weight ≥ 2.5 kg
* Parent/legal acceptable representative willing and able to provide informed consent.
* Parent/legal acceptable representative able to attend all scheduled visits and comply with all trial procedures.
* Parent/legal acceptable representative willing to permit venipuncture for purposes of collecting a blood sample.
* Previously enrolled in the 2-month-old group in Study GRC27 or approved by sponsor for enrollment as control.

Exclusion Criteria

* Reported allergy to egg proteins, chicken proteins, or any other constituent of Fluzone vacccine.
* Previous history of influenza vaccination (Group 2 subjects only).
* Receipt of any vaccine in the 14 days prior to enrollment.
* An acute illness with or without fever (rectal temperature ≥ 38.0 °C \[or ≥100.4 °F\]) in the 72 hours preceding enrollment in the trial.
* Known bleeding disorder.
* Participation in any other interventional (e.g., vaccine, drug) clinical trial (except Study GRC27) within 30 days prior to enrollment, or planned participation in another interventional clinical trial prior to termination of the subject's participation in this study.
* Known or suspected impairment of immunologic function or receipt of immunosuppressive therapy or immunoglobulin since birth.
* Personal or immediate family history of congenital immune deficiency.
* Developmental delay, neurologic disorder, or seizure disorder.
* Chronic medical, congenital or developmental disorder that could interfere with trial conduct or completion.
* Known human immunodeficiency virus (HIV)-positive or hepatitis B surface antigen (HBsAg)-positive mother.
* Known HIV, hepatitis B, or hepatitis C infection.
* Receipt of blood or blood-derived products within the past 2 months.
* Prior history of Guillain-Barré syndrome.
* Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.

Minimum Eligible Age

6 Months

Maximum Eligible Age

11 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes